[1]郝捷，陈万青．2012中国肿瘤登记年报．北京：军事医学科学出版社，2012．

[2]张玉玲，庹吉妤，郑荣寿，等．中国2009年恶性淋巴瘤发病与死亡分析．中国肿瘤，2013，22（5）：338-343．

[3]Swerdlow SH，Campo E，Harris NL，et al．WHO classification of tumours of haematopoietic and lymphoid tissues（4th ed）．Lyon：IARC，2008．

[4]Jaffe ES，Harris NL，Stein H，et al．Classification of lymphoid neoplasms：the microscope as a tool for disease discovery．Blood，2008，112（12）：4384-4399．

[5]Cheson BD．Role of functional imaging in the management of lymphoma．J Clin Oncol，2011，29（14）：1844-1854．

[6]Isasi CR，Lu P，Blaufox MD．A meta analysis of ¹⁸F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma．Cancer，2005，104（5）：1066-1074．

[7]La Fougere C，Hundt W，Brockel N，et al．Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma．Eur J Nucl Med Mol Imaging，2006，33（12）：1417-1425．

[8]Seam P，Juweid ME，Cheson BD．The role of FDG-PET scans in patients with lymphoma．Blood，2007，110（10）：3507-3516．

[9]Rodriguez-Vigil B，Gomez-Leon N，Pinilla I，et al．PET/CT in lymphoma：prospective study of enhanced fulldose PET/CT versus unenhanced low-dose PET/CT．J Nucl Med，2006，47（10）：1643-1648．

[10]Schaefer NG，Hany TF，Taverna C，et al．Non-Hodgkin lymphoma and Hodgkin disease：coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT？Radiology，2004，232（3）：823-829．

[11]Cheson BD，Horning SJ，Coiffier B，et al．Report of an International Workshop to standardize response criteria for Non-Hodgkin’s Lymphomas．J Clin Oncol，1999，17（4）：1244-1244．

[12]NCCN Clinical Practice Guidelines in Oncology，Hodgkin’s Lymphomas v．2．2014．http：//www．nccn．org/ professionals/physcian_gls/PDF/hl．pdf．

[13]NCCN Clinical Practice Guidelines in Oncology，Non-Hodgkin’s Lymphomas v．1．2014．http：//www．nccn．org/professionals/physcian_gls/PDF/nhl．pdf．

[14]Cheson BD，Pfistner B，Juweid ME，et al．Revised response criteria for malignant lymphoma．J Clin Oncol，2007，25（5）：579-586．

[15]Alvarez Páez AM，Nogueiras Alonso JM，Serena Puig A． ¹⁸F-FDG-PET/CT in lymphoma：two decades of experience．Rev Esp Med Nucl Imagen Mol，2012，31（6）：340-349．

[16]Hoffmann M，Kletter K，Becherer A，et al． ^18F-fluorodeoxyglucose positron emission tomography（ ^18F-FDGPET）for staging and follow-up of marginal zone B-cell lymphoma．Oncology，2003，64（4）：336-340．

[17]Hutchings M，Mikhaeel NG，Fields PA，et al．Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma．Ann Oncol，2005，16（7）：1160-1168．

[18]Cerci JJ，Pracchia LF，Linardi CC，et al． ^18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma．J Nucl Med，2010，51（9）：1337-1343．

[19]Gallamini A，Hutchings M，Rigacci L，et al．Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma：a report from a joint Italian-Danish study．J Clin Oncol，2007，25（24）：3746-3752．

[20]Dupuis J，Itti E，Rahmouni A，et al．Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma：integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria．Ann Oncol，2009，20（3）：503-507．

[21]Haioun C，Itti E，Rahmouni A，et al．[18F]fluoro-2-deoxy-D-glucose positron emission tomography（FDG-PET）in aggressive lymphoma：an early prognostic tool for predicting patient outcome．Blood，2005，106（4）：1376-1381．

[22]Spaepen K，Stroobants S，Dupont P，et al．Early restaging positron emission tomography with（18）F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma．Ann Oncol，2002，13（9）：1356-1363．

[23]Moskowitz CH，Schoder H，Teruya-Feldstein J，et al．Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma．J Clin Oncol，2010，28（11）：1896-1903．

[24]Sher DJ，Mauch PM，Van Den Abbeele A，et al．Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma：the importance of involved-field radiotherapy．Ann Oncol，2009，20（11）：1848-1853．

[25]Mocikova H，Obrtlikova P，Vackova B，et al．Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma：a retrospective study．Ann Oncol，2010，21（6）：1222-1227 ．

[26]El-Galaly T，Mylam KJ，Brown P，et al．Positron emission tomography/ computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs．Haematologica，2012，97（6）：931-936．

[27]Goldschmidt N，Or O，Klein M，et al．The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma．Ann Hematol，2011，90（2）：165-171．

[28]Zinzani PL，Stefoni V，Tani M，et al．Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma．J Clin Oncol，2009，27（11）：1781-1787．

[29]Petrausch U，Samaras P，Haile SR，et al．Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy．Ann Oncol，2010，21（8）：1694-1698．

[30]Schoder H，Noy A，Gonen M，et al．Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma．J Clin Oncol，2005，23（21）：4643-4651．

[31]Karam M，Novak L，Cyriac J，et al．Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas．Cancer，2006，107（1）：175-183．

[32]Noy A，Schoder H，Gonen M，et al．The majority of transformed lymphomas have high standardized uptake values（SUVs）on positron emission tomography（PET）scanning similar to diffuse large B-cell lymphoma（DLBCL）．Ann Oncol，2009，20（3）：508-512．

[33]Zinzani PL，Musuraca G，Alinari L，et al．Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma．Clin Lymphoma Myeloma，2007，7（4）：291-295．

[34]Le Dortz L，De Guibert S，Bayat S，et al．Diagnostic and prognostic impact of ¹⁸F-FDG PET/CT in follicular lymphoma．Eur J Nucl Med Mol Imaging，2010，37（12）：2307-2314．

[35]Salles G，Seymour JF，Offner F，et al．Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy（PRIMA）：a phase 3，randomised controlled trial．The Lancet，2011，377（9759）：42-51．

[36]Terasawa T，Lau J，Bardet S，et al．Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma：a systematic review．J Clin Oncol，2009，27（11）：1906-1914．

[37]Spaepen K，Stroobants S，Dupont P，et al．Prognostic value of pretransplantation positron emission tomography using fluorine 18- fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation．Blood，2003，102（1）：53-59．

[38]Svoboda J，Andreadis C，Elstrom R，et al．Prognostic value of PDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation．Bone Marrow Transplant，2006，38（3）：211-216．

[39]Schot BW，Zijlstra JM，Sluiter WJ，et al．Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma．Blood，2007，109（2）：486-491．

[40]Derenzini E，Musuraca G，Fanti S，et al．Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma．Cancer，2008，113（9）：2496-2503．

[41]Johnston PB，Wiseman GA，Micallef IN．Positron emission tomography using F-18 fluorodeoxyglucose pre-and postautologous stem cell transplant in non-Hodgkin’s lymphoma．Bone Marrow Transplant，2008，41（11）：919-925．